Skip to content

Insulet PODD Stock-Based Comp

Stock-Based Comp at other companies

Medtronic logo
MedtronicMDT
West Pharmaceutical Services logo
West Pharmaceutical ServicesWST

Other financials

Income statement

See full
Revenue$761.7M+33.9%
Gross profit$529.0M+29.3%
Operating income$122.1M+37.5%
Net income$91.1M+157%
EPS (diluted)$1.30+160%

Balance sheet

See full
Cash & equivalents$480.4M-62.6%
Total debt$969.7M-45.5%
Total equity$1.3B-2.1%
Total assets$3.0B-15.1%

Cash flow

See full
Operating cash flow$113.8M+78.4%
CapEx$24.3M+97.6%
Free cash flow$89.5M+73.8%

Valuation

See full
Market cap$10.1B-19.9%
Enterprise value$10.59B-19.4%
P/E33.3×+2.0×
P/S3.5×-2.3×

Profitability

See full
Gross margin71%+0.6pp
Operating margin17.5%+2.0pp
Net margin10.4%-7.9pp
FCF margin14.3%+1.1pp

Returns & leverage

See full
Return on equity23%-14.9pp
Debt / equity0.7×-0.6×
Current ratio2.5×-2.0×

Where this comes from

Reported directly by Insulet in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Insulet’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Insulet's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Insulet's stock-based comp?
Insulet (PODD) reported stock-based comp of $21.3M in Q1 2026.
How has Insulet's stock-based comp changed year-over-year?
Insulet's stock-based comp increased by 17.0% year-over-year, from $18.2M to $21.3M.
What is the long-term trend for Insulet's stock-based comp?
Over 4 years (2021 to 2025), Insulet's stock-based comp has grown at a 16.2% compound annual growth rate (CAGR), from $34.4M to $62.7M.